Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of glp-1 receptor in type 1 diabetic rat hearts

Experimental Diabetes Research

Volumn 2011, Issue , 2011, Pages

  Artinian, Shushan B ^a   Al Lafi, Sawsan M ^a   Boutary, Suzan S ^a   Bitar, Khalil M ^a   Zwainy, Nadine S ^a   Bikhazi, Anwar B ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; BOVINE INSULIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN GLARGINE; IODINE 125; RENIN INHIBITOR; AMIDE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; FUMARIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; PEPTIDE; RENIN; STREPTOZOCIN; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HEART; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART PERFUSION; HEART PROTECTION; HEART WEIGHT; HORMONE RECEPTOR INTERACTION; INSULIN DEPENDENT DIABETES MELLITUS; ISOTOPE LABELING; MALE; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL DIABETES MELLITUS; HEART MUSCLE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; SPRAGUE DAWLEY RAT;

AMIDES; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EVALUATION, PRECLINICAL; FUMARATES; GLUCAGON-LIKE PEPTIDE 1; HEART; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIUM; PEPTIDES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; RENIN; STREPTOZOCIN; VENOMS;

EID: 80052749880     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2011/489708     Document Type: Article

References (28)

1. Braga M. F., Leiter L. A., Role of renin-angiotensin system blockade in patients with diabetes mellitus The American Journal of Cardiology 2009 104 6 835 839
2. Marks J. B., Raskin P., Cardiovascular risk in diabetes: a brief review Journal of Diabetes Complications 2000 14 2 108 115 (Pubitemid 30665761)
3. Elahi D., Egan J. M., Shannon R. P., GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide Obesity 2008 16 7 1501 1509 (Pubitemid 351915102)
4. Drucker D. J., The role of gut hormones in glucose homeostasis Journal of Clinical Investigation 2007 117 1 24 32 (Pubitemid 46048446)
5. Inzucchi S. E., McGuire D. K., New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond Circulation 2008 117 4 574 584
6. Knop F. K., Vilsbolll T., Hojberg P. V., Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007 56 8 1951 1959 (Pubitemid 47195814)
7. Dupre J., Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans Regulatory Peptides 2005 128 2 149 157 (Pubitemid 40380915)
8. Lee S., Yabe D., Nohtomi K., Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes Journal of Endocrinology 2010 57 2 119 126
9. Scheen A. J., Renin-angiotensin system inhibition prevents type 2 diabetes mellituspart 1: a meta-analysis of randomised clinical trials Diabetes and Metabolism 2004 30 6 487 496 (Pubitemid 40070350)
10. Allikmets K., Aliskiren-an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension Vascular Health and Risk Management 2007 3 6 809 815
11. Cheng J. W., Aliskiren: renin inhibitor for hypertension management Clinical Therapeutics 2008 30 1 31 47 (Pubitemid 351834725)
12. Dubois E. A., Cohen A. F., Aliskiren British Journal of Pharmacology 2009 68 5 653 654
13. Pimenta E., Oparil S., Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors Therapeutics and Clinical Risk Management 2009 5 3 459 464
14. Chandramouli V., Carter J. R., Cell membrane changes in chronically diabetic rats Diabetes 1975 24 3 257 262
15. Al Jaroudi W. A., Nuwayri-Salti N., Usta J. A., Effect of insulin and angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus Journal of Hypertension 2005 23 2 381 392 (Pubitemid 40279642)
16. Bikhazi A. B., Khalife A. M., Jaroudi W. A., Endothelin-1 receptor subtypes expression and binding in a perfused rat model of myocardial infarction Comparative Biochemistry and PhysiologyPart C: Toxicology and Pharmacology 2003 134 1 35 43 (Pubitemid 36091947)
17. Haddad R. E., Jurjus A. R., Ibrahim M. Z., Binding of 125I-insulin on capillary endothelial and myofiber cell membranes in normal and streptozotocin-induced diabetic perfused rat hearts Comparative Biochemistry and PhysiologyA Physiology 1997 117 4 523 530 (Pubitemid 27293597)
18. Ban K., Noyan-Ashraf M. H., Hoefer J., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 2008 117 18 2340 2350 (Pubitemid 351653542)
19. Hui H., Farilla L., Merkel P., Perfetti R., The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects European Journal of Endocrinology 2002 146 6 863 869 (Pubitemid 34705080)
20. George C. M., Future trends in diabetes management Nephrology Nursing Journal 2009 36 5 477 483
21. Zhou Q., Du J., Hu Z., Evidence for adipose-muscle cross talk: opposing regulation of muscle proteolysis by adiponectin and Fatty acids Endocrinology 2007 148 12 5696 5705 (Pubitemid 350146142)
22. Bugger H., Abel E. D., Rodent models of diabetic cardiomyopathy Disease Models and Mechanisms 2009 2 9-10 454 466
23. Garg S., Moser E., Dain M. P., Clinical experience with insulin glargine in type 1 diabetes Diabetes Technology and Therapeutics 2010 12 11 835 846
24. Kang Y. S., Lee M. H., Song H. K., Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice Nephrology Dialysis Transplantation 2010 26 4 1194 1204
25. Kirino Y., Sato Y., Kamimoto T., Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats Journal of Endocrinology 2009 200 1 53 61
26. Burcelin R., EuCSGLP-1, What is known, new and controversial about GLP-1? minutes of the 1st European GLP-1 Club Meeting, Marseille Diabetes and Metabolism 2008 34 6 627 630
27. Nystrom T., Gutniak M. K., Zhang Q., Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease American Journal of Physiology Endocrinology and Metabolism 2004 287 6 E1209 E1215 (Pubitemid 39491964)
28. Dong Y. F., Liu L., Kataoka K., prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes Diabetologia 2010 53 1 180 191